FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
wasinington,	D.C.	20343	

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kearns Evan					2. Issuer Name and Ticker or Trading Symbol Cogent Biosciences, Inc. [COGT]							(Ch	eck all application	able)	Person(s) to Is 10% (Other		
(Last)	`	irst) SCIENCES, INC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/03/2021								below)				
200 CAMBRIDGE PARK DRIVE, SUITE 2500				-													
(Street)			02140	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	e) X Form fil Form fil					
(City)	(5	State)	(Zip)														
		Та	ble I - Non-D			ecuritie	s Acc	quired, [Disp	osed o	of, or Be	neficiall	y Owned				
Date			Transaction te onth/Day/	Execution Date,		Code (Instr.			5. Amoun Securities Beneficia Owned For Reported	s Form ally (D) collowing (I) (II	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								Code V Amount (A) or (D)				Price	Transaction(s) (Instr. 3 and 4)			(1130.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	saction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		ties ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership tt (Instr. 4)				
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	.(-)		
Stock Option (Right to Buy)	\$8.93	05/03/2021		A		260,000		(1)	05	5/03/2031	Common Stock	260,000	\$0.00	260,000	D		

Explanation of Responses:

1. This stock option shall vest over a four year period as follows: 1/4th of the option shall vest one year after the vesting start date; then 1/48th of the option shall vest monthly over the remaining three year period.

Remarks:

/s/ Ryan Murr, Attorney-in-Fact 05/05/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.